These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 9929499

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions.
    Fischer V, Johanson L, Heitz F, Tullman R, Graham E, Baldeck JP, Robinson WT.
    Drug Metab Dispos; 1999 Mar; 27(3):410-6. PubMed ID: 10064574
    [Abstract] [Full Text] [Related]

  • 4. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s.
    Prueksaritanont T, Gorham LM, Ma B, Liu L, Yu X, Zhao JJ, Slaughter DE, Arison BH, Vyas KP.
    Drug Metab Dispos; 1997 Oct; 25(10):1191-9. PubMed ID: 9321523
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability.
    Lampen A, Christians U, Guengerich FP, Watkins PB, Kolars JC, Bader A, Gonschior AK, Dralle H, Hackbarth I, Sewing KF.
    Drug Metab Dispos; 1995 Dec; 23(12):1315-24. PubMed ID: 8689938
    [Abstract] [Full Text] [Related]

  • 7. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin.
    Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, Benet LZ, Christians U.
    Drug Metab Dispos; 2000 Nov; 28(11):1369-78. PubMed ID: 11038166
    [Abstract] [Full Text] [Related]

  • 8. Biotransformation of lovastatin. II. In vitro metabolism by rat and mouse liver microsomes and involvement of cytochrome P-450 in dehydrogenation of lovastatin.
    Vyas KP, Kari PH, Prakash SR, Duggan DE.
    Drug Metab Dispos; 1990 Nov; 18(2):218-22. PubMed ID: 1971576
    [Abstract] [Full Text] [Related]

  • 9. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
    Kumar GN, Dykstra J, Roberts EM, Jayanti VK, Hickman D, Uchic J, Yao Y, Surber B, Thomas S, Granneman GR.
    Drug Metab Dispos; 1999 Aug; 27(8):902-8. PubMed ID: 10421617
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The interaction of diltiazem with lovastatin and pravastatin.
    Azie NE, Brater DC, Becker PA, Jones DR, Hall SD.
    Clin Pharmacol Ther; 1998 Oct; 64(4):369-77. PubMed ID: 9797793
    [Abstract] [Full Text] [Related]

  • 12. Biotransformation of lovastatin--III. Effect of cimetidine and famotidine on in vitro metabolism of lovastatin by rat and human liver microsomes.
    Vyas KP, Kari PH, Wang RW, Lu AY.
    Biochem Pharmacol; 1990 Jan 01; 39(1):67-73. PubMed ID: 2297361
    [Abstract] [Full Text] [Related]

  • 13. Human liver cytochrome P4503A biotransformation of the cyclosporin derivative SDZ IMM 125.
    Vickers AE, Meyer E, Dannecker R, Keller B, Tynes RE, Maurer G.
    Drug Metab Dispos; 1995 Mar 01; 23(3):321-6. PubMed ID: 7628296
    [Abstract] [Full Text] [Related]

  • 14. Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies.
    Pasha MK, Muzeeb S, Basha SJ, Shashikumar D, Mullangi R, Srinivas NR.
    Biomed Chromatogr; 2006 Mar 01; 20(3):282-93. PubMed ID: 16143964
    [Abstract] [Full Text] [Related]

  • 15. Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes.
    Toda T, Eliasson E, Ask B, Inotsume N, Rane A.
    Basic Clin Pharmacol Toxicol; 2009 Nov 01; 105(5):327-32. PubMed ID: 19663817
    [Abstract] [Full Text] [Related]

  • 16. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
    Niwa T, Shiraga T, Mitani Y, Terakawa M, Tokuma Y, Kagayama A.
    Drug Metab Dispos; 2000 Sep 01; 28(9):1128-34. PubMed ID: 10950860
    [Abstract] [Full Text] [Related]

  • 17. Characterization of the cytochrome P450 enzymes involved in the metabolism of a new cardioprotective agent KR-33028.
    Kim H, Yoon YJ, Kim H, Kang S, Cheon HG, Yoo SE, Shin JG, Liu KH.
    Toxicol Lett; 2006 Oct 10; 166(2):105-14. PubMed ID: 16857327
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.
    Zhou-Pan XR, Sérée E, Zhou XJ, Placidi M, Maurel P, Barra Y, Rahmani R.
    Cancer Res; 1993 Nov 01; 53(21):5121-6. PubMed ID: 8221648
    [Abstract] [Full Text] [Related]

  • 20. Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8.
    Tornio A, Pasanen MK, Laitila J, Neuvonen PJ, Backman JT.
    Basic Clin Pharmacol Toxicol; 2005 Aug 01; 97(2):104-8. PubMed ID: 15998357
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.